Cardiovascular Systems to Webcast Fiscal 2011 Third-Quarter Earnings Conference Call Wednesday, May 4
April 28 2011 - 12:15PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a
live webcast of its fiscal 2011 third-quarter conference call on
Wednesday, May 4, 2011, at 3:45 p.m. CT (4:45 p.m. ET). David L.
Martin, president and chief executive officer, and Laurence L.
Betterley, chief financial officer, will discuss the company’s
results for its fiscal third quarter ended March 31, 2011, and its
financial outlook. The company will issue a post-market earnings
release on May 4.
To access the live webcast, go to the investor information
section of the company’s website, www.csi360.com, on the day of the
conference call and click on the webcast icon. A webcast replay
will be available beginning at 7 p.m. CT the same day.
To participate in the conference call, dial (888) 713-4218 and
enter 61587023. Please dial in at least 10 minutes prior to the
call. To pre-register for the call, log on to the following
website:
https://www.theconferencingservice.com/prereg/key.process?key=PPKUFV8TA.
When joining the call, pre-registered participants can enter their
PIN code, and other participants can press *0 to reach the
operator, or wait on the line for operator assistance.
If you do not have access to the Internet and want to listen to
an audio replay of the conference call, dial (888) 286-8010 and
enter access number 71171713. The audio replay will be available
beginning at 8 p.m. CT on Wednesday, May 4, 2011, through 6 p.m. CT
on Friday, May 6, 2011.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
innovative solutions for treating vascular and coronary disease.
The company’s Stealth 360°™, Diamondback 360® and Diamondback
Predator 360® Orbital PAD Systems treat calcified and fibrotic
plaque in arterial vessels throughout the leg in a few minutes of
treatment time, and address many of the limitations associated with
existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of
the Diamondback 360° in August 2007 and for the Stealth 360° in
March 2011. To date, more than 37,000 PAD procedures have been
performed using the Diamondback 360° in leading institutions across
the United States.
CSI has also commenced its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its Diamondback 360° System in treating coronary arteries. The
coronary system is under clinical investigation and is currently
not commercially available in the United States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024